Savara (SVRA) Other financing activities (2010 - 2026)
Savara's (SVRA) quarterly Other financing activities came in at $45000.0 in Q1 2026, down 72.73% year-on-year from $165000.0 in Q1 2025, and down 61.54% on a QoQ basis from $117000.0 in Q4 2025.
Savara (SVRA) Other financing activities (2010 - 2026) Analysis & Trends
Savara (SVRA) has 14 years of Other financing activities data on file, last reported at $45000.0 in Q1 2026.
- On a quarterly basis, Other financing activities fell 72.73% year-over-year to $45000.0 in Q1 2026; TTM through Mar 2026 was $227000.0, a 87.6% increase from a year earlier, with the FY2025 full-year figure at $347000.0, up 4857.14% from the prior year.
- Other financing activities for Q1 2026 stood at $45000.0, down from $117000.0 in the prior quarter.
- Over the last five years, Other financing activities for SVRA reached as high as $237000.0 in Q3 2024 and fell as low as -$292000.0 in Q4 2024.
- Historically, Other financing activities has averaged $56833.3 across 4 years, with a median of $64000.0 in 2023.
- Across the five-year window, Other financing activities sank 428.09% in 2024 and jumped 490.91% in 2025, its largest moves.
- Year by year, Other financing activities stood at $89000.0 in 2023, then sank by 428.09% to -$292000.0 in 2024, then jumped by 140.07% to $117000.0 in 2025, then slumped by 61.54% to $45000.0 in 2026.
- Per Business Quant data, the three most recent Other financing activities figures were $45000.0 in Q1 2026, $117000.0 in Q4 2025, and $65000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Savara | 1.24 Bn | 1.24 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 45,000.00 |
| Mar 31, 2026 | 45,000.00 |
| Dec 31, 2025 | 117,000.00 |
| Dec 31, 2025 | 117,000.00 |
| Jun 30, 2025 | 65,000.00 |
| Jun 30, 2025 | 65,000.00 |
| Mar 31, 2025 | 165,000.00 |
| Mar 31, 2025 | 165,000.00 |
| Dec 31, 2024 | -292,000.00 |
| Dec 31, 2024 | -292,000.00 |
| Sep 30, 2024 | 237,000.00 |
| Sep 30, 2024 | 237,000.00 |
| Jun 30, 2024 | 11,000.00 |
| Jun 30, 2024 | 11,000.00 |
| Mar 31, 2024 | 51,000.00 |
| Mar 31, 2024 | 51,000.00 |
| Dec 31, 2023 | 89,000.00 |
| Dec 31, 2023 | 89,000.00 |
| Sep 30, 2023 | 63,000.00 |
| Sep 30, 2023 | 63,000.00 |